Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Ophthalmol. 2011 May;95(5):620-3. doi: 10.1136/bjo.2010.182097. Epub 2011 Mar 3.

What hope for the future? GNAQ and uveal melanoma.

Author information

1
Academic Unit of Ophthalmology and Orthoptics, Department of Oncology, K Floor, School of Medicine & Biomedical Sciences, Faculty of Medicine, Dentistry & Health, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK. k.sisley@sheffield.ac.uk

Abstract

Uveal melanomas (UM) are aggressive ocular tumours that spread to the liver. They are characterised by alterations of chromosome 3 and 8, which are highly predictive of a poor prognosis. Unfortunately, being able to identify those patients with aggressive disease has not, as yet, translated into improved survival. Recently, mutations of guanine nucleotide-binding protein G(q) subunit alpha (GNAQ, or G-alpha-q), which effectively turn it into a dominantly acting oncogene, have been identified in approximately half of UM. These mutations are specific to UM and other non-cutaneous melanomas, and are not found in normal tissues, thus making them potential therapeutic targets. Here, the authors review the background to GNAQ in UM and explore what makes it such an interesting target for the future treatment of patients.

PMID:
21378004
DOI:
10.1136/bjo.2010.182097
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center